Case Comprehensive Cancer Center
This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.
Myelofibrosis is a type of bone cancer that mainly affects the elderly. Myeolofibrosis can either develop on its own, or it can be caused by other blood cell conditions. Myeolofibrosis causes scarring in the bone marrow that makes it hard to produce healthy read blood cells. This increases the risk of participants developing anemia at diagnosis, but eventually most affected participants develop anemia. Anemia is a complication of using Janus Kinase inhibitors, which are the main agents used to treat MF. Almost half of the participants who develop anemia require red blood cell transfusion suppo…
Inclusion Criteria: * Patients with myelofibrosis as defined by WHO criteria - either primary or secondary myelofibrosis with: * Anemia: * Transfusion Dependent: ≥3 units transfused in the 12 weeks immediately preceding C1D1. * Non-Transfusion Dependent: had ≥3 Hb level measurements of ≤10 g/dL recorded on ≥3 different days with no RBC transfusions in the 12 weeks immediately preceding C1D1. * Thrombocytopenia: Platelet count of ≤150 at any time after signing informed consent. * Age ≥18 years * Participant has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2…
Luspatercept will be given through subjecutaneous injection on Day 1of each cycle at a dose of 1.33-1.75mg/kg.
Pacritinib will be given twice daily orally at a dose of 200mg.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.